R H B Benedict1, I Fishman, M M McClellan, R Bakshi, B Weinstock-Guttman. 1. Department of Neurology, State University of New York (SUNY), Buffalo School of Medicine and Biomedical Sciences, Buffalo General Hospital, Buffalo, New York 14203, USA. benedict@buffalo.cdu
Abstract
INTRODUCTION: The Beck Depression Inventory-Fast Screen (BDI-FS) is a brief self-report inventory designed to evaluate depression in patients with medical illness. As depressive disorder is especially prominent in multiple sclerosis (MS), a cost-effective procedure for identifying depressive disorder in MS is sorely needed. The BDI-FS may be useful in this regard although, to date, its validity in MS patients has not been assessed. METHODS: Fifty-four consecutive MS patients were studied. All underwent psychological assessment, which included the BDI-FS and other self-report measures of depression. Forty-eight caregiver/informants were interviewed using the Neuorpsychiatric Inventory (NPI). Retrospective chart reviews were conducted by a single trained research assistant, blind to the results of psychological testing and interviews, to determine if antidepressant medications had been prescribed. RESULTS: The BDI-FS was significantly correlated with other self-report measures of depression (P < 0.001) and with informant reported dysphoria (P < 0.01), In addition, BDI-FS scores discriminated MS patients undergoing treatment for depressive disorder from untreated MS patients (P = 0.01). CONCLUSION: These data support the concurrent and discriminative validity of the BDI-FS in MS. As the test is brief and not confounded with neurological symptoms, it is recommended for depression screening in this population.
INTRODUCTION: The Beck Depression Inventory-Fast Screen (BDI-FS) is a brief self-report inventory designed to evaluate depression in patients with medical illness. As depressive disorder is especially prominent in multiple sclerosis (MS), a cost-effective procedure for identifying depressive disorder in MS is sorely needed. The BDI-FS may be useful in this regard although, to date, its validity in MS patients has not been assessed. METHODS: Fifty-four consecutive MS patients were studied. All underwent psychological assessment, which included the BDI-FS and other self-report measures of depression. Forty-eight caregiver/informants were interviewed using the Neuorpsychiatric Inventory (NPI). Retrospective chart reviews were conducted by a single trained research assistant, blind to the results of psychological testing and interviews, to determine if antidepressant medications had been prescribed. RESULTS: The BDI-FS was significantly correlated with other self-report measures of depression (P < 0.001) and with informant reported dysphoria (P < 0.01), In addition, BDI-FS scores discriminated MS patients undergoing treatment for depressive disorder from untreated MS patients (P = 0.01). CONCLUSION: These data support the concurrent and discriminative validity of the BDI-FS in MS. As the test is brief and not confounded with neurological symptoms, it is recommended for depression screening in this population.
Authors: Myla D Goldman; Robert W Motl; John Scagnelli; John H Pula; Jacob J Sosnoff; Diego Cadavid Journal: Neurology Date: 2013-10-30 Impact factor: 9.910
Authors: F A H van der Linden; J J Kragt; M Klein; H M van der Ploeg; C H Polman; B M J Uitdehaag Journal: J Neurol Neurosurg Psychiatry Date: 2005-12 Impact factor: 10.154
Authors: Katherine Treadaway; Gary Cutter; Amber Salter; Sharon Lynch; James Simsarian; John Corboy; Douglas Jeffery; Bruce Cohen; Ken Mankowski; Joseph Guarnaccia; Lawrence Schaeffer; Roy Kanter; David Brandes; Charles Kaufman; David Duncan; Ellen Marder; Arthur Allen; John Harney; Joanna Cooper; Douglas Woo; Olaf Stüve; Michael Racke; Elliot M Frohman Journal: J Neurol Date: 2009-04-27 Impact factor: 4.849